MBOT Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -- compared to Microbot Medical, Inc.'s net margin of -12425.36%. Microbot Medical, Inc.'s return on equity of -45.11% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Microbot Medical, Inc. has a consensus price target of $8.75, signalling upside risk potential of 269.2%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 412.82%. Given that Perspective Therapeutics, Inc. has higher upside potential than Microbot Medical, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Microbot Medical, Inc..

Microbot Medical, Inc. has a beta of 1.171, which suggesting that the stock is 17.1% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

Microbot Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Microbot Medical, Inc. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Microbot Medical, Inc.'s net income of -$3.6M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Microbot Medical, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical, Inc. is -- versus 162.73x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -- compared to Microbot Medical, Inc.'s net margin of -862.39%. Microbot Medical, Inc.'s return on equity of -45.11% beat VolitionRX Ltd.'s return on equity of --.

Microbot Medical, Inc. has a consensus price target of $8.75, signalling upside risk potential of 269.2%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.60 which suggests that it could grow by 767.53%. Given that VolitionRX Ltd. has higher upside potential than Microbot Medical, Inc., analysts believe VolitionRX Ltd. is more attractive than Microbot Medical, Inc..

Microbot Medical, Inc. has a beta of 1.171, which suggesting that the stock is 17.1% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Microbot Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Microbot Medical, Inc. quarterly revenues are --, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Microbot Medical, Inc.'s net income of -$3.6M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Microbot Medical, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical, Inc. is -- versus 20.54x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of -- compared to Microbot Medical, Inc.'s net margin of 17.41%. Microbot Medical, Inc.'s return on equity of -45.11% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

Microbot Medical, Inc. has a consensus price target of $8.75, signalling upside risk potential of 269.2%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $346.07 which suggests that it could grow by 23.5%. Given that Microbot Medical, Inc. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe Microbot Medical, Inc. is more attractive than West Pharmaceutical Services, Inc..

Microbot Medical, Inc. has a beta of 1.171, which suggesting that the stock is 17.1% more volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.617%.

Microbot Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.3% to investors and pays a quarterly dividend of $0.22 per share. Microbot Medical, Inc. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Microbot Medical, Inc. quarterly revenues are --, which are smaller than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Microbot Medical, Inc.'s net income of -$3.6M is lower than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Microbot Medical, Inc.'s price-to-earnings ratio is -- while West Pharmaceutical Services, Inc.'s PE ratio is 41.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical, Inc. is -- versus 6.77x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -- compared to Microbot Medical, Inc.'s net margin of 3.93%. Microbot Medical, Inc.'s return on equity of -45.11% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Microbot Medical, Inc. has a consensus price target of $8.75, signalling upside risk potential of 269.2%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 143.51%. Given that Microbot Medical, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Microbot Medical, Inc. is more attractive than Xtant Medical Holdings, Inc..

Microbot Medical, Inc. has a beta of 1.171, which suggesting that the stock is 17.1% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Microbot Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Microbot Medical, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Microbot Medical, Inc.'s net income of -$3.6M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Microbot Medical, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 60.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical, Inc. is -- versus 0.67x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.